D64. 81 - Anemia due to antineoplastic chemotherapy | ICD-10-CM.
ICD-10 code D61. 9 for Aplastic anemia, unspecified is a medical classification as listed by WHO under the range - Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism .
Complications of Cancer TreatmentICD-10-CM CodeICD-10-CM DescriptionD61.1Drug-induced aplastic anemia (aplastic anemia due to antineoplastic chemotherapy)D61.810Antineoplastic chemotherapy induced pancytopeniaD64.81Anemia due to antineoplastic chemotherapyD70.1Agranulocytosis secondary to cancer chemotherapy19 more rows
ICD-10-CM Code for Anemia in neoplastic disease D63. 0.
ICD-10-CM Code for Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter T45. 1X5A.
Overview. Aplastic anemia is a condition that occurs when your body stops producing enough new blood cells. The condition leaves you fatigued and more prone to infections and uncontrolled bleeding. A rare and serious condition, aplastic anemia can develop at any age.
Antineoplastic drugs are medications used to treat cancer. Other names for antineoplastic drugs are anticancer, chemotherapy, chemo, cytotoxic, or hazardous drugs.
810 for Antineoplastic chemotherapy induced pancytopenia is a medical classification as listed by WHO under the range - Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism .
Chemotherapy-induced anemia (CIA) is a consequence of malignant invasion of normal tissue leading to blood loss, bone marrow infiltration with disruption of erythropoiesis, and functional iron deficiency as a consequence of inflammation.
1 for Encounter for antineoplastic chemotherapy and immunotherapy is a medical classification as listed by WHO under the range - Factors influencing health status and contact with health services .ICD-10 code Z51.1 for Encounter for antineoplastic chemotherapy and ...https://www.aapc.com › codes › icd-10-codeshttps://www.aapc.com › codes › icd-10-codes
Definition. Anemia (NOS) is a decrease in the number of red blood cells. Many cancer patients develop anemia due to the cancer and/or cancer therapy. This condition may be referred to as Anemia in neoplastic disease or anemia of chronic disorders. The anemia by itself is not reportable.Anemia - SEER Hematopoietic and Lymphoid Neoplasm Databasehttps://seer.cancer.gov › seertools › hemelymphhttps://seer.cancer.gov › seertools › hemelymph
D63. 0 - Anemia in neoplastic disease. ICD-10-CM.D63.0 - Anemia in neoplastic disease | ICD-10-CM - Unbound Medicinehttps://www.unboundmedicine.com › ICD-10-CM › allhttps://www.unboundmedicine.com › ICD-10-CM › all
The 2022 edition of ICD-10-CM D61.2 became effective on October 1, 2021.
D50-D89 Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism
D64.81 is a valid billable ICD-10 diagnosis code for Anemia due to antineoplastic chemotherapy . It is found in the 2021 version of the ICD-10 Clinical Modification (CM) and can be used in all HIPAA-covered transactions from Oct 01, 2020 - Sep 30, 2021 .
DO NOT include the decimal point when electronically filing claims as it may be rejected. Some clearinghouses may remove it for you but to avoid having a rejected claim due to an invalid ICD-10 code, do not include the decimal point when submitting claims electronically. See also:
A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion '), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous such as tumors in different quadrants of the same breast, codes for each site should be assigned.
When a pregnant woman has a malignant neoplasm, a code from subcategory O9A.1 -, malignant neoplasm complicating pregnancy, childbirth, and the puerperium, should be sequenced first, followed by the appropriate code from Chapter 2 to indicate the type of neoplasm. Encounter for complication associated with a neoplasm.
When a primary malignancy has been previously excised or eradicated from its site and there is no further treatment directed to that site and there is no evidence of any existing primary malignancy at that site, a code from category Z85, Personal history of malignant neoplasm, should be used to indicate the former site of the malignancy. Any mention of extension, invasion, or metastasis to another site is coded as a secondary malignant neoplasm to that site. The secondary site may be the principal or first-listed with the Z85 code used as a secondary code.
The neoplasm table in the Alphabetic Index should be referenced first. However, if the histological term is documented, that term should be referenced first, rather than going immediately to the Neoplasm Table, in order to determine which column in the Neoplasm Table is appropriate. Alphabetic Index to review the entries under this term and the instructional note to “see also neoplasm, by site, benign.” The table provides the proper code based on the type of neoplasm and the site. It is important to select the proper column in the table that corresponds to the type of neoplasm. The Tabular List should then be referenced to verify that the correct code has been selected from the table and that a more specific site code does not exist.
Chapter 2 of the ICD-10-CM contains the codes for most benign and all malignant neoplasms. Certain benign neoplasms , such as prostatic adenomas, may be found in the specific body system chapters. To properly code a neoplasm, it is necessary to determine from the record if the neoplasm is benign, in-situ, malignant, or of uncertain histologic behavior. If malignant, any secondary ( metastatic) sites should also be determined.
When the reason for admission/encounter is to determine the extent of the malignancy, or for a procedure such as paracentesis or thoracentesis, the primary malignancy or appropriate metastatic site is designated as the principal or first-listed diagnosis, even though chemotherapy or radiotherapy is administered.
When a patient is admitted because of a primary neoplasm with metastasis and treatment is directed toward the secondary site only , the secondary neoplasm is designated as the principal diagnosis even though the primary malignancy is still present .